Tags

Type your tag names separated by a space and hit enter

Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Eur Urol. 2009 May; 55(5):1003-11.EU

Abstract

BACKGROUND

Recent large, prospective, randomised studies have demonstrated that adjuvant radiotherapy (RT) is a safe and effective procedure for preventing disease recurrence in locally advanced prostate cancer (PCa) patients. However, no study has ever tested the role of adjuvant RT in node-positive patients after radical prostatectomy (RP).

OBJECTIVE

We hypothesised that adjuvant RT with early hormone therapy (HT) might improve long-term outcomes of patients with PCa and nodal metastases treated with RP and extended pelvic lymph node dissection (ePLND).

DESIGN, SETTING, AND PARTICIPANTS

This retrospective study included 250 consecutive patients with pathologic lymph node invasion. We assessed factors predicting long-term biochemical recurrence (BCR)-free and cancer-specific survival (CSS) in node-positive PCa patients treated with RP, ePLND, and adjuvant treatments between 1988 and 2002 in a tertiary academic centre.

INTERVENTION

All patients received adjuvant treatments according to the treating physician after detailed patient information: 129 patients (51.6%) were treated with a combination of RT and HT, while 121 patients (48.4%) received adjuvant HT alone.

MEASUREMENTS

BCR-free survival and CSS in patients with node-positive PCa.

RESULTS AND LIMITATIONS

Mean follow-up was 95.9 mo (median: 91.2). BCR-free survival and CSS rates at 5, 8, and 10 yr were 72%, 61%, 53% and 89%, 83%, 80%, respectively. In multivariable Cox regression models, adjuvant RT and the number of positive nodes were independent predictors of BCR-free survival (p=0.002 and p=0.003, respectively) as well as of CSS (p=0.009 and p=0.01, respectively). Moreover, there was significant gain in predictive accuracy when adjuvant RT was included in multivariable models predicting BCR-free survival and CSS (gain: 3.3% and 3%, respectively; all p<0.001).

CONCLUSIONS

Our data showed excellent long-term outcome for node-positive PCa patients treated with radical surgery plus adjuvant treatments. This study is the first to report a significant protective role for adjuvant RT in BCR-free survival and CSS of node-positive patients.

Authors+Show Affiliations

Department of Urology, Vita-Salute University, Milan, Italy. dapozzo.luigi@hsr.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

19211184

Citation

Da Pozzo, Luigi F., et al. "Long-term Follow-up of Patients With Prostate Cancer and Nodal Metastases Treated By Pelvic Lymphadenectomy and Radical Prostatectomy: the Positive Impact of Adjuvant Radiotherapy." European Urology, vol. 55, no. 5, 2009, pp. 1003-11.
Da Pozzo LF, Cozzarini C, Briganti A, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol. 2009;55(5):1003-11.
Da Pozzo, L. F., Cozzarini, C., Briganti, A., Suardi, N., Salonia, A., Bertini, R., Gallina, A., Bianchi, M., Fantini, G. V., Bolognesi, A., Fazio, F., Montorsi, F., & Rigatti, P. (2009). Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. European Urology, 55(5), 1003-11. https://doi.org/10.1016/j.eururo.2009.01.046
Da Pozzo LF, et al. Long-term Follow-up of Patients With Prostate Cancer and Nodal Metastases Treated By Pelvic Lymphadenectomy and Radical Prostatectomy: the Positive Impact of Adjuvant Radiotherapy. Eur Urol. 2009;55(5):1003-11. PubMed PMID: 19211184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. AU - Da Pozzo,Luigi F, AU - Cozzarini,Cesare, AU - Briganti,Alberto, AU - Suardi,Nazareno, AU - Salonia,Andrea, AU - Bertini,Roberto, AU - Gallina,Andrea, AU - Bianchi,Marco, AU - Fantini,Gemma V, AU - Bolognesi,Angelo, AU - Fazio,Ferruccio, AU - Montorsi,Francesco, AU - Rigatti,Patrizio, Y1 - 2009/02/04/ PY - 2008/11/20/received PY - 2009/01/26/accepted PY - 2009/2/13/entrez PY - 2009/2/13/pubmed PY - 2009/10/27/medline SP - 1003 EP - 11 JF - European urology JO - Eur Urol VL - 55 IS - 5 N2 - BACKGROUND: Recent large, prospective, randomised studies have demonstrated that adjuvant radiotherapy (RT) is a safe and effective procedure for preventing disease recurrence in locally advanced prostate cancer (PCa) patients. However, no study has ever tested the role of adjuvant RT in node-positive patients after radical prostatectomy (RP). OBJECTIVE: We hypothesised that adjuvant RT with early hormone therapy (HT) might improve long-term outcomes of patients with PCa and nodal metastases treated with RP and extended pelvic lymph node dissection (ePLND). DESIGN, SETTING, AND PARTICIPANTS: This retrospective study included 250 consecutive patients with pathologic lymph node invasion. We assessed factors predicting long-term biochemical recurrence (BCR)-free and cancer-specific survival (CSS) in node-positive PCa patients treated with RP, ePLND, and adjuvant treatments between 1988 and 2002 in a tertiary academic centre. INTERVENTION: All patients received adjuvant treatments according to the treating physician after detailed patient information: 129 patients (51.6%) were treated with a combination of RT and HT, while 121 patients (48.4%) received adjuvant HT alone. MEASUREMENTS: BCR-free survival and CSS in patients with node-positive PCa. RESULTS AND LIMITATIONS: Mean follow-up was 95.9 mo (median: 91.2). BCR-free survival and CSS rates at 5, 8, and 10 yr were 72%, 61%, 53% and 89%, 83%, 80%, respectively. In multivariable Cox regression models, adjuvant RT and the number of positive nodes were independent predictors of BCR-free survival (p=0.002 and p=0.003, respectively) as well as of CSS (p=0.009 and p=0.01, respectively). Moreover, there was significant gain in predictive accuracy when adjuvant RT was included in multivariable models predicting BCR-free survival and CSS (gain: 3.3% and 3%, respectively; all p<0.001). CONCLUSIONS: Our data showed excellent long-term outcome for node-positive PCa patients treated with radical surgery plus adjuvant treatments. This study is the first to report a significant protective role for adjuvant RT in BCR-free survival and CSS of node-positive patients. SN - 1873-7560 UR - https://www.unboundmedicine.com/medline/citation/19211184/Long_term_follow_up_of_patients_with_prostate_cancer_and_nodal_metastases_treated_by_pelvic_lymphadenectomy_and_radical_prostatectomy:_the_positive_impact_of_adjuvant_radiotherapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(09)00085-2 DB - PRIME DP - Unbound Medicine ER -